Tipranavir and Voriconazole: Interaction Details

Brand names
Tipranavir
Aptivus
Voriconazole
Vfend
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

What Happens When You Take Tipranavir With Voriconazole

What can happen when they are taken together (rated Major)

Altered voriconazole exposure, an increased tipranavir exposure, an increased risk of tipranavir-related adverse reactions, an increased risk of voriconazole-related adverse reactions and reduced of voriconazole

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Tipranavir acts as both an and an of , so using it together with voriconazole can change voriconazole exposure in either direction (higher or lower). The voriconazole dose should be adjusted, and patients should be monitored for voriconazole adverse reactions as well as for a lack of efficacy.

In addition, tipranavir is an HIV and a , and giving it with voriconazole may raise tipranavir exposure, which may enhance the efficacy of tipranavir. The tipranavir dosage should be lowered, with monitoring for adverse reactions.1

The Tipranavir and Voriconazole Interaction, Explained

Tipranavir (Aptivus) is an HIV medicine, and voriconazole (Vfend) treats serious fungal infections. Taken together, they can change how much of each drug is in your body. Tipranavir levels may go up, which can raise the chance of side effects like nausea, diarrhea, or liver problems. Voriconazole levels can go up or down, so it could cause more side effects or work less well against the infection.

This is a known interaction that care teams manage. Keep taking both as prescribed. Your doctor or pharmacist may adjust the doses and check on you more closely. Tell them about any new symptoms.

Mechanism: Tipranavir (boosted with ritonavir) has mixed effects on , with both and , so voriconazole exposure may rise or fall unpredictably. Voriconazole inhibits , a pathway for tipranavir , which may raise tipranavir exposure.

  • Effects: variable voriconazole (risk of toxicity or subtherapeutic levels and reduced ); increased tipranavir exposure and adverse reactions.
  • Onset/evidence: delayed; probable; severity major.
  • Management: adjust voriconazole dose and monitor for adverse reactions and lack of efficacy (consider voriconazole TDM). Reduce tipranavir dose and monitor frequently for adverse reactions (e.g., ).

See the 2 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Tipranavir and Voriconazole Interact

The likely mechanism

of -mediated of voriconazole; of -mediated metabolism of tipranavir; inhibition of CYP2C19-mediated metabolism of voriconazole

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Tipranavir and Voriconazole Interaction

Your care team can manage this interaction by tailoring doses and monitoring.

  • Your voriconazole dose may need to be adjusted and individualized, with attention to both side effects and whether the infection is responding.
  • Your tipranavir dose may be reduced, and your team may monitor you more closely for side effects.
  • Keep taking both medicines as prescribed. Do not change or stop either on your own.
  • Tell your pharmacist or prescriber about new or worsening symptoms, and about any other medicines you take.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Tipranavir or Voriconazole need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

8 reports from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: VFEND oral tablets, oral suspension, intravenous injection, voriconazole oral tablets, oral suspension, intravenous injection

    In an independent published study, voriconazole (400 mg every 12 hours on Day 1, then 200 mg every 12 hours on Day 2) given together with a single intravenous 5 microgram/kg dose of fentaNYL (a ) raised the mean (0 to inf) of fentaNYL 1.4-fold (range 0.81- to 2.04-fold).1

  2. Report 2 · Study title

    Prescribing information: VFEND oral tablets, oral suspension, intravenous injection, voriconazole oral tablets, oral suspension, intravenous injection

    In another independent published study, multiple oral doses of voriconazole (400 mg every 12 hours on Day 1, followed by five doses of 200 mg every 12 hours on Days 2 to 4) were coadministered with a single 10 mg oral dose of oxyCODONE (a ) on Day 3. The mean and (0 to inf) of oxyCODONE rose by 1.7-fold (range 1.4- to 2.2-fold) and 3.6-fold (range 2.7- to 5.6-fold), respectively, and the mean of oxyCODONE was prolonged 2.0-fold (range 1.4- to 2.5-fold).1

  3. Report 3 · Study title

    Prescribing information: VFEND oral tablets, oral suspension, intravenous injection, voriconazole oral tablets, oral suspension, intravenous injection

    In stable transplant recipients on chronic therapy with cycloSPORINE (a ), concurrent oral voriconazole (200 mg every 12 hours for 8 days) raised cycloSPORINE by an average of 1.1 times (90% CI: 0.9, 1.41) and (tau) by an average of 1.7 times (90% CI: 1.5, 2.0), compared with cycloSPORINE given without voriconazole.1

  4. Report 4 · Study title

    Prescribing information: VFEND oral tablets, oral suspension, intravenous injection, voriconazole oral tablets, oral suspension, intravenous injection

    In a drug interaction study of 6 healthy male subjects, oral voriconazole (400 mg every 12 hours for 1 day, then 200 mg every 12 hours for 2.5 days) was given concurrently with oral fluconazole (a ) (400 mg on day 1, then 200 mg every 24 hours for 4 days). Voriconazole and (tau) increased by an average of 57% (90% CI: 20%, 107%) and 79% (90% CI: 40%, 128%), respectively. In a follow-on clinical study of 8 healthy male subjects, lowering the dose and/or frequency of voriconazole and fluconazole did not eliminate or reduce this effect.1

  5. Report 5 · Study title

    Prescribing information: VFEND oral tablets, oral suspension, intravenous injection, voriconazole oral tablets, oral suspension, intravenous injection

    In a drug interaction study in healthy subjects, rifAMPin (a strong ) (600 mg once daily) lowered the and (tau) of voriconazole (200 mg every 12 hours x 7 days) by an average of 93% and 96%, respectively. Increasing the voriconazole dose to 400 mg every 12 hours does not restore adequate voriconazole exposure during with rifAMPin.1

  6. Report 6 · Study title

    Prescribing information: VFEND oral tablets, oral suspension, intravenous injection, voriconazole oral tablets, oral suspension, intravenous injection

    In an independent published study, healthy volunteers received multiple oral doses of St. John's Wort (a ) (300 mg LI 160 extract three times daily for 15 days) followed by a single 400 mg oral dose of voriconazole, and mean voriconazole (0 to inf) fell by 59%. By contrast, coadministering single oral doses of St. John's Wort and voriconazole had no appreciable effect on voriconazole AUC(0 to inf). Long-term use of St. John's Wort could lead to reduced voriconazole exposure.1

  7. Report 7 · Study title

    Prescribing information: VFEND oral tablets, oral suspension, intravenous injection, voriconazole oral tablets, oral suspension, intravenous injection

    Oral letermovir (a ) coadministered with oral voriconazole reduced the and (0-12) of voriconazole by an average of 39% and 44%, respectively.1

  8. Report 8 · Study title

    Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents

    Bi-directional is possible between voriconazole and such as tipranavir and ritonavir. High dose ritonavir (400 milligrams (mg)) given twice daily decreased the area under the concentration-time curve of voriconazole by 82%, whereas the effect of low dose ritonavir (100 to 400 mg/day) has not been evaluated. Until more data are available, voriconazole should not be coadministered with tipranavir in combination with ritonavir.2

Tipranavir and Voriconazole: Common Questions

How serious is the Tipranavir and Voriconazole interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Tipranavir and Voriconazole interaction managed?

Your care team can manage this interaction by tailoring doses and monitoring. Your voriconazole dose may need to be adjusted and individualized, with attention to both side effects and whether the infection is responding. Your tipranavir dose may be reduced, and your team may monitor you more closely for side effects. Keep taking both medicines as prescribed. Do not change or stop either on your o… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "delayed". Effects tend to build up gradually over days to weeks.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Tipranavir and Voriconazole Interaction

Ask in your own words about taking Tipranavir and Voriconazole together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (2)

  1. Product Information: VFEND(R) oral tablets, oral suspension, intravenous injection, voriconazole oral tablets, oral suspension, intravenous injection. Roerig (per FDA), New York, NY, 2025. DailyMed
  2. ANON: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. United States Department of Health and Human Services. Rockville, MD, USA. 2005.
Was this write-up helpful?

Other Serious Interactions of Tipranavir and Voriconazole

Also serious with Tipranavir

Also serious with Voriconazole

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Tipranavir

With Voriconazole

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks. This interaction.
  • UnspecifiedThe timing of this interaction is not well characterized.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.